Global Bioimplants Market 2017-2021
Bioimplants are used to regularize the physiological functions or augment the functioning of an existing biological structure to treat the cause of various chronic diseases such as cardiovascular diseases (CVDs), neurological disorders, dental issues, and ophthalmic complications. The demand for bioimplants is growing from cardiology, vascular therapy, orthopedic, trauma, spine, dental, and wound care. Bioengineered products such as cardiac pacemakers and orthopedic artificial implants are implanted inside the patient's body.
Technavio’s analysts forecast the global bioimplants market to grow at a CAGR of 10.20% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global bioimplants market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Bioimplants Market 2017-2021
Technavio recognizes the following companies as the key players in the global bioimplants market: Abbott, DePuy Synthes, Medtronic, Stryker, and Zimmer Biomet.
Other Prominent Vendors in the market are: B. Braun, Cook Medical, Corin, C. R. Bard, Edwards Lifesciences, FH Orthopedics, Kasios, KLS martin GROUP, Mediplus, W. L. Gore & Associates, and Wright Medical technology.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is increasing demand for minimally invasive surgeries. Minimally invasive surgeries involve creating a minute incision to reach the point of surgical intervention. Minimally invasive procedures such as laser surgery, endoscopy, and laparoscopy create small incisions, which significantly helps in reducing pain and morbidity and improve postoperative recovery.”
According to the report, one driver in the market is rising prevalence of chronic diseases. The demand for bioimplants has been increasing over the years due to the rising prevalence of chronic diseases such as CVDs, sensory and neurological diseases, orthopedic and spinal-related conditions, ophthalmic diseases, and dental diseases. Some of the common diseases chronic diseases are type 2 diabetes, obesity, stroke, cancer, obesity, arthritis, and heart diseases. With the increasing prevalence of diabetes, the risk CVDs also increases. Obesity is also one of the significant risk factors for type 2 diabetes.
Further, the report states that one challenge in the market is high cost of bioimplants. Currently, bioimplants are used to treat various chronic ailments such as type 2 diabetes, heart failure, obesity, and knee fracture. However, these implants are expensive as they are made from a combination of biological, mechanical, and optical elements. Bioimplants have properties that enable them to function inside the human body. Biomaterials have biomechanical properties, which are comparable to autogenous tissues. However, they do not have any side-effects. Some properties determine the suitability of materials for bioimplants.
Abbott, DePuy Synthes, Medtronic, Stryker, Zimmer Biomet, B. Braun, Cook Medical, Corin, C. R. Bard, Edwards Lifesciences, FH Orthopedics, Kasios, KLS martin GROUP, Mediplus, W. L. Gore & Associates, and Wright Medical technology.